Modulatory role of D-chiro-inositol (DCI) on LH and insulin secretion in obese PCOS patients

Gynecological Endocrinology

Volumn 30, Issue 6, 2014, Pages 438-443

  Genazzani, Alessandro D ^a   Santagni, Susanna ^a   Rattighieri, Erika ^a   Chierchia, Elisa ^a   Despini, Giulia ^a   Marini, Giulia ^a   Prati, Alessia ^a   Simoncini, Tommaso ^b  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Body mass index; Insulin resistance; Insulin sensitizer; Polycystic ovary syndrome

Indexed keywords

ANDROSTENEDIONE; D CHIRO INOSITOL; FOLLITROPIN; GONADORELIN; INOSITOL; INSULIN; LUTEINIZING HORMONE; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BODY MASS; CLINICAL ARTICLE; DIABETES MELLITUS; DRUG EFFICACY; FEMALE; FOLLITROPIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RELEASE; INSULIN RESPONSE; INSULIN SENSITIVITY; LIFESTYLE MODIFICATION; LUTEINIZING HORMONE BLOOD LEVEL; LUTEINIZING HORMONE RELEASE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; TREATMENT DURATION; ADENOHYPOPHYSIS; ADULT; BLOOD; CHEMISTRY; CLINICAL TRIAL; COMPLICATION; DIAGNOSTIC USE; DIET SUPPLEMENTATION; DIET THERAPY; FAMILY HEALTH; HYPERINSULINISM; INSULIN RESISTANCE; ITALY; PANCREAS ISLET BETA CELL; PATHOPHYSIOLOGY; SECRETION (PROCESS); STEREOISOMERISM;

ADULT; BODY MASS INDEX; DIETARY SUPPLEMENTS; FAMILY HEALTH; FEMALE; GONADOTROPIN-RELEASING HORMONE; HUMANS; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; INOSITOL; INSULIN; INSULIN RESISTANCE; INSULIN-SECRETING CELLS; ITALY; LUTEINIZING HORMONE; OBESITY; OVERWEIGHT; PITUITARY GLAND, ANTERIOR; POLYCYSTIC OVARY SYNDROME; STEREOISOMERISM;

EID: 84901273189     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.3109/09513590.2014.897321     Document Type: Article

References (33)

1. The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-Term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41-7
2. Ciampelli M, Fulghesu AM, Cucinelli F, et al. Impact of insulin and body mass index on metabolic and endocrine variables in polycystic ovary syndrome. Metab Clin Exp 1999;48:167-72. (Pubitemid 29072269
3. Genazzani AD, Battaglia C, Malavasi B, et al. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004;81:114-9. (Pubitemid 38058335
4. Dunaif A. Insulin resistance and the polycystic ovary syndrome: Mechanism and implications for pathogenesis. Endocr Rev 1997;18: 774-800. (Pubitemid 28009567
5. Palomba S, Falbo A, Zullo F, Orio F. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: A comprehensive review. Endocr Rev 2009;30:1-50
6. Berga SL. Polycystic ovary sybdrome: A model of combinatorial endocrinology? J Clin Endocrinol Metab 2009;94:2250-1
7. Salley KES, Winchkam EP, Cheang KI, et al. Glucose intolerance in polycystic ovary syndrome: A positin statement of the Androgen Excess Society. J Clin Endocrinol Metab 2007;92: 4546-56. (Pubitemid 350223423
8. Baillargeon JP, Nestler JE, Ostlund RE, et al. Greek hyperinsulinemic women, with or without polycycstic ovary syndrome, display altered inositols metabolism. Hum Reprod 2008;23:1439-46. (Pubitemid 351770579
9. Cattrall FR, Healy DL. Long-Term metabolic, cardiovascular and neoplastic risks with polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol 2004;18:803-12. (Pubitemid 40424612
10. Genazzani AD, Ricchieri F, Lanzoni C. Use of metformin in the treatment of polycystic ovary syndrome. Women's Health 2010;6: 577-93
11. Pasquali R, Gambineri A, Cavazza C, et al. Heterogeneity in the responsiveness to long-Term lifestyle intervention and predictability in obese women with polycystic ovary syndrome. Eur J Endocrinol 2011;164:53-60
12. Orchard TJ, Temprosa M, Goldberg R, et al Diabetes Prevention Program Research Group. The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: The Diabetes Prevention Program randomized trial. Ann Intern Med 2005;142: 611-9
13. Genazzani AD, Lanzoni C, Ricchieri F, et al. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol 2007;23:146-52. (Pubitemid 46570211
14. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24:139-44. (Pubitemid 351365855
15. Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1993;340:1314-20
16. Romero G, Larner J. Insulin mediators and the mechanism of insulin action. Adv Pharmacol 1993;24:21-50
17. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE, et al. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006;29:300-5. (Pubitemid 44106508
18. Baillargeon JP, Nestler JE. Commentary: Polycystic ovary syndrome: A syndrome of ovarian hypersensitivity to insuliñ J Clin Endocrinol Metab 2006;91:22-4
19. Larner J. D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 2002;3: 47-60. (Pubitemid 35174544
20. Sun TH, Heimark DB, Nguygen T, et al. Both myo-inositol to chiroinositol epimerase activities and chiro-inositol to myo-inositol ratios are decreased in tissues of GK type 2 diabetic rats compared to Wistar controls. Biochem Biophys Res Commun 2002;293:1092-8. (Pubitemid 34694154
21. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 Consensus on diagnostic criteria and longterm health risks related to polycycstic ovary syndrome. Fertil Steril 2004;81:19-25
22. Genazzani AD, Chierchia E, Rattighieri E, et al. Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS. Gynecol Endocrinol 2010;26:684-9
23. Genazzani AD, Prati A, Santagni S, et al. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol 2012;28:969-73
24. Genazzani AD, Santagni S, Chierchia E, et al. Estimation of instantaneous secretory rates and intrinsic characteristics of luteinizing hormone secretion in women with Kallmann syndrome before and after estriol administration. Reproductive Biology 2011;3: 284-93
25. Oerter KE, Guardabasso V, Rodabrd D. Detection and characterization of peaks and estimation of instantaneous secretory rate for episodic pulsatile hormone secretion. Comput Biomed Res 1986;19: 170-91. (Pubitemid 16080306
26. Legro RS, Finegood D, Dunaif A. Fasting glucose to insulin ratio is a useful measure of insulin sensitivity in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1998;83:2694-8. (Pubitemid 28493762
27. Galazis N, Galazi M, Atiomo W. D-Chiro-inositol and its significance in polycystic ovary syndrome: A systematic review. Gynecol Endocrinol 2011;27:256-62
28. Morgante G, Orvieto R, Di Sabatino A, et al. The role of inositol supplementation in patients with polycycstic ovary syndrome, with insulin resistance, undergoing the low-Dose gonadotropin ovulation induction regimen. Fertil Steril 2011;95:2642-4
29. Zacche MM, Caputo L, Filippis S, et al. Efficacy of myoinositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25:508-13
30. Unfer V, Carlomagno G, Dante G, Facchinetti F. Effects of myoinositol in women with PCOS: A systematic review of randomized controlled trials. Gynecol Endocrinol 2012;28:509-15
31. Gerli S, Papaleo E, Ferrari A, di Renzo GC. Randomized, double blind placebo-controlled trial: Effects of myo-inositol on ovarian function and metabolic factors in women with PCOS. Eur Rev Med Pharmacol Sci 2007;11:347-54. (Pubitemid 350200349
32. Villeneuve MC, Ostlund RE, Baiòòargeon JP. Hyperinsulinemia is closely related to low urinary clearance of D-chiro-inositol in men with a wide range of insulin sensitivity. Metab Clin Exp 2009;58: 62-8
33. Patel K, Coefler MS, Dahan MH, et al. Increased luteinizing hormone secretion in women with polycystic ovary syndrome is unaltered by prolonged insulin infusion. J Clin Endocrinol Metab 2003;88:5456-61. (Pubitemid 37452754